Study details
Enrolling now
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT IDNCT06205836ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
33
Study length
about 4 years
Ages
18+
Locations
1 site in MD
What this study is about
Researchers are testing the safety and effectiveness of cemiplimab, either alone or with fianlimab, in older adults (70+) diagnosed with localized or locally advanced microsatellite unstable colorectal cancer. The trial will last for approximately 1448 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cemiplimab
- 2.Take Fianlimab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
cemiplimab
Endpoints
Primary: Complete Response Rate
Body systems
Oncology